Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q41508355

about

Role of mTOR Inhibitors in Kidney Disease Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Sequence of treatment in locally advanced and metastatic renal cell carcinoma Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Individualising treatment choices in a crowded treatment algorithm Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Renal cell carcinoma.Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.How to facilitate early diagnosis of CNS involvement in malignant lymphoma.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma.Treatment-related mortality with everolimus in cancer patients.Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium Renal cell carcinoma: molecular biology and targeted therapy Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma.Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.Kidney cancer and 2014: is innovation really over?Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis.New advances in genitourinary cancer: evidence gathered in 2014.Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Clinical management of metastatic kidney cancer: the role of new molecular drugs.Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.

P2860

Q26747506-5AC96820-E3C2-4021-BC01-441DD40F2579 Q26751341-EFA75B14-6C6E-4691-9286-F4D662182665 Q26766240-E9C45EFC-1483-4219-BDEC-52C59DAE4F93 Q26773653-FB9CBD5C-696F-4F3D-8FAE-089B618D4A50 Q26783514-6BD462AE-6833-408E-ADB1-F0BC7509E624 Q27023669-7F2263F0-481B-4223-A0B7-0322B9A06BC7 Q28079861-2E3EF645-0CFA-4440-A45F-582D046B94F6 Q30235364-BA1F8054-1DCA-4783-8FE1-2798D2A62C9E Q30382892-A4D4ACB0-15A7-41F5-8538-F0FAD68EACFD Q31133442-71AB4276-C767-4989-AB83-417CF0DDF5C0 Q33633424-FA9F4FCD-25CB-4076-B3E3-FED28ADC6F37 Q33684941-ADCAB778-9896-40CF-A8F3-A29B49C714C7 Q33699582-E4417613-F6F9-457A-BCDA-0724DD715AE0 Q33749070-3E895ABF-78D0-495D-B473-58606EF0B65C Q33779585-4FA8B4D6-44E5-454B-BEAB-D095E9E9473E Q34183978-F03CAAE0-4CBF-46C6-9F28-616B40457D2F Q34513914-ED835E56-CA04-4B11-978F-973F12C944EC Q35063752-B0A15698-555C-4BF7-8D8D-197C05856143 Q35315403-37D59A52-8157-477B-8DB3-28BEE976AEE4 Q35549876-C04903F4-7A1F-4A0A-AFD9-BA4FA170F3B9 Q35677757-E724F7AF-24E6-443F-A25E-CF98B91DB116 Q36062302-13DE5538-7CB0-414E-8FFD-91E4C9F902F5 Q36252946-E8C1F1D8-9020-4AA6-ABC6-F504AB62AE26 Q36893510-4680216E-E304-489F-B6CA-26F8A3F2E87C Q36932702-50383CFC-0F0B-45B5-B2A2-1E41434A5F71 Q37179808-65ABC477-4F7F-4B61-9F7C-60DAA4A57DFB Q37217474-770CC7AD-8FD1-4892-BC5D-3EE958AC1FD6 Q37220273-9F59D6E2-9AF4-415C-94B4-1B061E0E9999 Q37433431-96746E77-EEDF-4254-90CA-FF39A340CDE0 Q37437544-45B22EC1-6FE4-45A1-BBA9-94AE82598105 Q38465870-0BF5A08A-DF9C-483F-BA4C-3E6529D0CCF5 Q38527936-796B962A-D6AD-4742-A6B5-D6E247632BBA Q38550942-EBE4974F-65B2-4386-8B0A-C2B2F9FAF4C5 Q38557894-D73377B3-3D20-4020-BCAA-8733B6262881 Q38586537-66E10B04-1400-4F48-B540-A8EF76D5DF5B Q38611436-47D7F36D-463E-47A4-A517-AB9F9E2C9887 Q38624864-ABC9BDA3-60A1-45F8-9E01-43DEC6E7AAF2 Q38627885-DA43A441-582F-4F22-B190-B95977598511 Q38652566-14DD89A3-4B35-4FC4-813F-EC84D7381714 Q38653213-9F138848-8603-4F3B-9D42-D3237AD9F0A8

P2860

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q41508355

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Phase II randomized trial comp ...... tastatic renal cell carcinoma.

@en

type

label

Phase II randomized trial comp ...... tastatic renal cell carcinoma.

@en

prefLabel

Phase II randomized trial comp ...... tastatic renal cell carcinoma.

@en

P1433

Q41508355-6BD6FAF6-EE85-49CB-86D3-30C29BDD02DA

P1476

Q41508355-9E2D5BC3-A917-44CD-821A-5885919406D4

P2093

Q41508355-0157238F-B9F9-47BA-B925-C3F22C5FEEB2

Q41508355-15B34787-99C3-483F-8AD3-53E89568D72A

Q41508355-2FE229F7-A5D4-4F00-B9B3-4366FA8408D6

Q41508355-4746F3EC-5CA0-4DE3-AE08-E684B44FE567

Q41508355-5DE99A83-0B36-4665-AECC-EEBBA39CF1EE

Q41508355-61961E9B-52E4-47C7-AB4F-D08ABBC16972

Q41508355-6D3A98E5-F41A-4B88-9B95-EBDE334D46FF

Q41508355-78E26DEA-5067-4926-92C7-FDFBD4B10EC3

Q41508355-7E5364DF-08F6-4CC8-8A2B-181848DE9636

Q41508355-7E788FC7-E539-41A4-8355-23C9457CCBAB

P2860

Q41508355-796C30DD-D56F-4CC7-B18B-62182707DCCF

Q41508355-93415A00-DE78-46B5-818C-BD9DE3F086AA

Q41508355-95FFB534-F03C-416D-AC2B-1BD029EC3D83

Q41508355-96CDED08-9373-43DC-9F9B-F4F44DF13896

Q41508355-AAD65229-AFDF-4762-9D00-53F609DF627C

Q41508355-BDF0E037-98AA-4E02-9643-FE6CCCDF0249

Q41508355-BF6B83C0-D329-4AD2-952C-5184E3944410

P304

Q41508355-356EA418-4C46-482B-994D-F1BA0D596BE7

P31

Q41508355-B5E4527D-9FF5-459D-9D1A-18B175CB453F

P356

Q41508355-9A0F3E6A-0B1A-4273-A664-043C202AE7AC

P407

Q41508355-E1991B08-30E0-4050-BABF-060CBC78F2A6

P433

Q41508355-5ED10875-8ED8-4D86-90DB-27E0834E81BC

P478

Q41508355-976A5543-C2D6-47E0-B930-22DD0128B10B

P50

Q41508355-2D2CC7B6-12C9-47C8-BA2E-0C02C4D998D3

Q41508355-4E7EDEA2-F858-4AD4-B404-47C64B5F493A

P577

Q41508355-F23DDDEE-169E-47DF-84D2-D7CEC46A3613

P698

Q41508355-CB9111DE-65AC-4A9E-B253-0D971C86072A

P921

Q41508355-BCC9C86C-CA9A-4C33-857D-DB2CF9F21710

P932

Q41508355-45869447-C747-43CD-BA68-9F0DFBC1836B

P356

JCO.2013.54.6911

P1433

Journal of Clinical Oncology

P1476

Phase II randomized trial comp ...... tastatic renal cell carcinoma.

@en

P2093

Carlos H Barrios

http://www.w3.org/2001/XMLSchema#string

Dalila Sellami

http://www.w3.org/2001/XMLSchema#string

Edward M Schiff

http://www.w3.org/2001/XMLSchema#string

Foon-Yiu Cheung

http://www.w3.org/2001/XMLSchema#string

J Thaddeus Beck

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Julie Niolat

http://www.w3.org/2001/XMLSchema#string

Ken Pittman

http://www.w3.org/2001/XMLSchema#string

Oezlem Anak

http://www.w3.org/2001/XMLSchema#string

Poulam Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

A proof of concept phase II non-inferiority criterion.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P304

2765-2772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.54.6911

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25049330

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

5569681

http://www.w3.org/2001/XMLSchema#string